During the corresponding time, United Therapeutics Corporation saw a revenue deteriorated by -1.92 % year on year, sequentially revenue grew by 0.23 %. While revenue at the United Therapeutics Corporation's corporate clients
United Therapeutics's Comment on Sales, Marketing and Customers
The company sells its products internationally through various distributors and wholesalers. Lilly manages purchase orders, invoicing, and collections for Adcirca, while retaining regulatory authority and control over retail pricing. Remodulin is sold outside the United States to distributors with exclusive rights in Europe, the Middle East, Asia, and South and Central America, with Grupo Ferrer Internacional, S.A. (Ferrer) serving as the primary distributor holding marketing authorization rights. Nebulized Tyvaso is sold exclusively in Japan through Mochida Pharmaceutical Co., Ltd., and to other exclusive distributors in Asia, the Middle East, and Latin America. In Canada, Remodulin and Unituxin are distributed via a specialty pharmaceutical wholesaler. Named-patient programs for Remodulin and Nebulized Tyvaso operate in certain countries. Exclusive agreements with Ferrer cover the distribution of Orenitram and Nebulized Tyvaso; however, the contract for Orenitram was terminated. Ferrer submitted a marketing authorization application for Nebulized Tyvaso in the United Kingdom for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin is distributed exclusively in Japan through Ohara Pharmaceutical Co., Ltd. Tyvaso DPI has not been approved or distributed outside the United States.
United Therapeutics’s Comment on Sales, Marketing and Customers
The company sells its products internationally through various distributors and wholesalers. Lilly manages purchase orders, invoicing, and collections for Adcirca, while retaining regulatory authority and control over retail pricing. Remodulin is sold outside the United States to distributors with exclusive rights in Europe, the Middle East, Asia, and South and Central America, with Grupo Ferrer Internacional, S.A. (Ferrer) serving as the primary distributor holding marketing authorization rights. Nebulized Tyvaso is sold exclusively in Japan through Mochida Pharmaceutical Co., Ltd., and to other exclusive distributors in Asia, the Middle East, and Latin America. In Canada, Remodulin and Unituxin are distributed via a specialty pharmaceutical wholesaler. Named-patient programs for Remodulin and Nebulized Tyvaso operate in certain countries. Exclusive agreements with Ferrer cover the distribution of Orenitram and Nebulized Tyvaso; however, the contract for Orenitram was terminated. Ferrer submitted a marketing authorization application for Nebulized Tyvaso in the United Kingdom for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin is distributed exclusively in Japan through Ohara Pharmaceutical Co., Ltd. Tyvaso DPI has not been approved or distributed outside the United States.
Sources:
United Therapeutics Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: United Therapeutics Corporation’s corporate clients.
For your research, we’ve provided 9 tables on United Therapeutics Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
83.86 %